Coenzyme Q10 (CoQ10 / Ubiquinol)

Cardiovascular is CoQ10's strongest case at 7.5/10 because the evidence reaches hard outcomes, not just biomarkers. In chronic heart failure, Mortensen 2014 (Q-SYMBIO, n=420) found 300 mg/day cut major adverse cardiac events from 26% to 15% (hazard ratio 0.50) and halved cardiovascular mortality over two years, and Lei 2017 pooled 14 RCTs (n=2,149) showing mortality risk ratio 0.69. The honest boundary is that blood pressure is a null result in the rigorous Cochrane synthesis and left-ventricular ejection fraction did not move significantly in the pooled data, so the win is mortality and exercise capacity in heart failure, not a blanket cardiovascular cure.

Mitochondrial support earns 7.0/10 because CoQ10 is a literal component of the respiratory chain, not a speculative one. It carries electrons between complexes I and III to produce ATP, so in states of genuine deficiency the rationale is mechanistic and direct. Primary CoQ10 deficiency and statin-induced depletion are the clearest cases: Banach 2015 confirmed statins lower plasma CoQ10 by 0.44 micromol/L, and replacing it has a coherent target. The score is held below the cardiovascular case because dedicated human trials measuring mitochondrial function as a clinical endpoint are fewer, and benefit in people with normal baseline CoQ10 is far less certain than in those with a measurable deficit.

Energy lands at 6.0/10, real for deficit states but oversold for healthy people. CoQ10's role in ATP synthesis makes restored energy plausible where levels are low, such as statin users, older adults, or those with fatigue tied to cardiac or mitochondrial issues, and exercise capacity improved in the heart-failure meta-analysis Lei 2017. The catch is that in healthy, replete individuals the controlled evidence for a noticeable energy lift is thin, and effects are gradual rather than stimulant-like. Treat it as a correction for a deficit, judged over weeks against your own exertion tolerance, not as a daily pick-me-up.

Longevity earns 6.0/10 on one unusually strong signal. In Alehagen 2013 (KiSel-10), 200 mg CoQ10 plus 200 micrograms selenium daily in elderly Swedes cut cardiovascular mortality from 12.6% to 5.9% over roughly five years, a striking outcome that persisted at ten-year follow-up. That is genuine hard-endpoint longevity-relevant data, rare among supplements. The honest caveat is that it was a combination with selenium in a selenium-low population, so the CoQ10-specific contribution is not cleanly isolated. It is enough to take seriously for older adults, especially those with cardiovascular risk, but not a proven standalone lifespan extender.

Antioxidant activity earns 5.5/10 because it is a defining feature of the molecule, not a marketing claim. CoQ10 is the main lipid-phase antioxidant in cell membranes and lipoproteins, where it regenerates vitamin E and limits LDL oxidation. Endothelial function improved meaningfully in a meta-analysis, Gao 2012 reporting a flow-mediated dilation effect size of 1.70 across five trials, which is a downstream antioxidant-linked outcome. The score is mid-range rather than high because raising antioxidant capacity is a mechanism, and the v2.0 rubric credits demonstrated clinical benefit over a moved marker; the real payoff shows up in the cardiovascular endpoints.

This captures statin-associated muscle pain specifically, at 5.5/10. The meta-analysis Qu 2018 pooled 12 RCTs (n=575) and found CoQ10 significantly reduced muscle pain, weakness, cramp, and tiredness, though creatine kinase did not change. The honest counterweight is Taylor 2015, a rigorous crossover in confirmed myopathy that found no benefit. The reconciliation: CoQ10 helps a meaningful share of statin users with muscle complaints but is not universal, so it is a cheap, safe, evidence-backed first thing to try before abandoning a needed statin.

Anti-inflammatory support sits at 5.0/10. Several trials report modest reductions in inflammatory markers like CRP and IL-6 with CoQ10, consistent with its membrane-antioxidant action, and this plausibly contributes to its cardiovascular effects. But few trials isolate inflammation as the primary clinical endpoint, so this is a supporting mechanism rather than a standalone reason to supplement. Define one marker if this is your goal and judge by it.

Male fertility earns 5.0/10. Several RCTs and meta-analyses report that CoQ10 improves sperm concentration, motility, and morphology and lowers seminal oxidative stress, with a coherent antioxidant mechanism. The honest limit is that improvements in semen parameters have not clearly translated into higher live-birth rates, and trials are heterogeneous. It is a reasonable, low-risk adjunct for men with oxidative-stress-linked subfertility, judged on a follow-up semen analysis.